FTSE 100 stocks to buy and hold until 2030

Rupert Hargreaves highlights four FTSE 100 stocks that he’d buy and hold until 2030, considering their growth prospects.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Finding stocks to buy and hold for the next decade is incredibly challenging. Indeed, there’s no road map or shortcut I can use to find FTSE 100 stocks that’ll be around 10 years from now. 

However, by focusing on well-run companies with a sustainable competitive advantage, I think I can improve my chances of finding a long term buy-and-forget forget investment. 

There are a handful of companies in the FTSE 100 that appear as if they have these qualities. I’d buy all of them for that reason. 

FTSE 100 stocks to buy 

A great place to start looking for companies with a sustainable competitive advantage is the pharmaceutical sector. When drugs companies develop a treatment, they’re protected by exclusive manufacturing rights for an extended period. This is their primary competitive advantage. The companies can effectively charge what they like for these products while they’ve exclusive manufacturing rights. 

I think AstraZeneca is one of the most exciting pharmaceutical companies listed on the London market. It has been spending billions developing cancer treatments, and these treatments are now becoming a significant revenue stream for the group. 

Unfortunately, exclusive manufacturing rights don’t last forever. When they come to an end, companies like Hikma can produce the same product at a lower cost. That’s why I would buy both Astra and Hikma.

While Astra has a great portfolio of exclusive treatments, Hikma’s one of the world’s largest producers of generic drugs. Its competitive advantage is its size. It can produce these drugs at a much lower cost than competitors. As the global healthcare sector grows, I think the demand for these services will only expand. 

Both of these companies also have significant pricing power, but they could come under pressure from regulators to lower costs. If they do, this is one of the biggest challenges they may have to overcome. 

Long-term outlook

As well as the pharmaceutical companies outlined above, I’d also by Legal & General to hold in my portfolio FTSE 100 stocks.

This company is built for the long term. Its primary lines of business are pension and life insurance. In both of these markets, the group has to have a multi-generation perspective. Consumers buying life insurance and pension products need to be sure the organisation will still be around when they come to use them.

As such, management has to make decisions with long-term success in mind. This is a fantastic quality for a buy-and-forget investment, in my opinion. 

I’d also require distribution group Bunzl. Investors should never use past performance to guide future potential, but this company has successfully grown to become one of the UK’s largest corporations over the past few decades. 

Through a combination of acquisitions and organic growth, the enterprise has gone from strength to strength. It’s now a force to be reckoned with in the relatively uninteresting distribution industry. Management has no plans to change its strategy anytime soon. That’s why I think the company can continue to grow for the next decade. 

Unfortunately, while both of these businesses may be doing everything in their power to build a solid organisation, there’s always going to be the chance a hidden risk will emerge. This could hurt growth, or even lead to asset sales.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has recommended Bunzl and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black colleagues high-fiving each other at work
Investing Articles

Why now could be the time to buy these recovering FTSE 100 growth shares!

Royston Wild is building a list of the FTSE's greatest shares to buy today. Here are two he thinks could…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

My Stocks and Shares ISA has two giant weeds in it. Should I pull them out?

This writer has two massive losers inside his Stocks and Shares ISA portfolio. What's gone wrong? And is it time…

Read more »

Mature black couple enjoying shopping together in UK high street
Investing Articles

7.5% dividend yield! 2 cheap passive income stocks to consider for a £1,500 payout

Royston Wild describes how large investment in these passive income stocks could provide a four-figure cash payout this year.

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Billionaires are selling Nvidia stock! I’d rather buy this AI share instead

With billionaire investors now banking profits in Nvidia stock, our writer considers an AI share that still looks to be…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

3 shares that could soar as the UK stock market wakes from its slumber

The UK stock market is on fire at the moment. If it keeps rising from here, Edward Sheldon reckons these…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is on fire! 2 top shares I’d still snap up

FTSE 100 shares as a whole might be setting records on a daily basis this month, but that doesn't mean…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

£11,000 in savings? Here’s how I’d aim to turn that into a £15,080-a-year second income

Buying dividend shares is how this Fool continues to build up his second income. With a lump sum of savings,…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Value Shares

This undervalued FTSE 250 stock could do well in the AI boom

As chip producers build manufacturing plants and data companies construct data centres, this hidden gem in the FTSE 250 could…

Read more »